These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 19568702

  • 1. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA, Waterbury LD.
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [Abstract] [Full Text] [Related]

  • 2. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
    Bucci FA, Waterbury LD.
    J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD.
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [Abstract] [Full Text] [Related]

  • 4. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD.
    Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
    [Abstract] [Full Text] [Related]

  • 5. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [Abstract] [Full Text] [Related]

  • 6. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
    Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS.
    Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
    [Abstract] [Full Text] [Related]

  • 7. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery.
    Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S.
    Acta Ophthalmol; 2009 May; 87(3):300-5. PubMed ID: 19183412
    [Abstract] [Full Text] [Related]

  • 8. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T, Raizman M, Ernest P, Gayton J, Lehmann R.
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [Abstract] [Full Text] [Related]

  • 9. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
    Waterbury LD, Silliman D, Jolas T.
    Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
    [Abstract] [Full Text] [Related]

  • 10. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group.
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
    Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group.
    Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
    [Abstract] [Full Text] [Related]

  • 12. Concentration and dosing of ketorolac versus bromfenac.
    Gayton J.
    J Cataract Refract Surg; 2009 Jul; 35(7):1319; author reply 1320. PubMed ID: 19545832
    [No Abstract] [Full Text] [Related]

  • 13. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
    Jones J, Francis P.
    Expert Opin Pharmacother; 2009 Oct; 10(14):2379-85. PubMed ID: 19735215
    [Abstract] [Full Text] [Related]

  • 14. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
    Waterbury LD, Galindo D, Villanueva L, Nguyen C, Patel M, Borbridge L, Attar M, Schiffman RM, Hollander DA.
    J Ocul Pharmacol Ther; 2011 Apr; 27(2):173-8. PubMed ID: 21351868
    [Abstract] [Full Text] [Related]

  • 15. Topical 0.1% Bromfenac Sodium for Intraoperative Miosis Prevention and Prostaglandin E2 Inhibition in Femtosecond Laser-Assisted Cataract Surgery.
    Chen H, Lin H, Chen W, Zhang B, Xiang W, Li J, Chen W.
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):193-201. PubMed ID: 28106471
    [Abstract] [Full Text] [Related]

  • 16. The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.
    Jung JW, Chung BH, Kim EK, Seo KY, Kim TI.
    Yonsei Med J; 2015 Nov; 56(6):1671-7. PubMed ID: 26446653
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery.
    Stewart R, Grosserode R, Cheetham JK, Rosenthal A.
    Clin Ther; 1999 Apr; 21(4):723-32. PubMed ID: 10363737
    [Abstract] [Full Text] [Related]

  • 18. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients.
    Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, Acular LS for Cystoid Macular Edema (ACME) Study Group.
    Am J Ophthalmol; 2008 Oct; 146(4):554-560. PubMed ID: 18599019
    [Abstract] [Full Text] [Related]

  • 19. Peripheral prostanoid levels and nonsteroidal anti-inflammatory drug analgesia: replicate clinical trials in a tissue injury model.
    Gordon SM, Brahim JS, Rowan J, Kent A, Dionne RA.
    Clin Pharmacol Ther; 2002 Aug; 72(2):175-83. PubMed ID: 12189364
    [Abstract] [Full Text] [Related]

  • 20. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor.
    Miyake K, Ogawa T, Tajika T, Gow JA, McNamara TR.
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):573-8. PubMed ID: 19049295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.